Human mammary tumor cell proliferation: primary role of platelet-derived growth factor and possible synergism with human α-fetoprotein
- Juan A. Leal,
- Bhushan K. Gangrade,
- John L. Kiser,
- Jeffrey V. May,
- Brooks A. Keel(corresponding author)
- University of Kansas,
- Wesley Medical Center
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Human mammary medullary carcinoma cells (passages 16 to 21) were cultured for 2 days to allow for attachment, followed by 6 days of culture in either fetal calf serum, human cord blood, human amniotic fluid, or growth factors in the presence or absence of purified human α-fetoprotein (AFP). When growth factors were tested alone, only platelet-derived growth factor produced a significant increase in cell proliferation. Although up to 40% amniotic fluid had no effect on cell proliferation, human cord blood was two-fold more potent than fetal calf serum at similar concentrations. The addition of 10 ng/ml of platelet-derived growth factor increased the proliferative activity of human cord blood 1.5- to 2.5-fold. Ablation of endogenous AFP by affinity chromatography reduced the proliferative activity of cord blood by 75%. Similarly, the mitogenic activity of cord blood plus platelet-derived growth factor was reduced by 56% when AFP was removed. Purified AFP dose-dependently enhanced the proliferative activity of platelet-derived growth factor. This synergistic effect was specific for platelet-derived growth factor. We conclude that platelet-derived growth factor is a major growth factor controlling the proliferation of these tumor cells and that AFP may enhance growth factor proliferative activity and human mammary tumor growth.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 247-251 (5 pages)Journal (Volume, Issue Number)
Steroids (Volume 56, Issue 5)Publication milestones
- Published - 05/1991
Publication status
ISSN
0039-128XPublication IDs
- Scopus: 0025868885
- PubMed: 1715100
